Prashant Kudva
VP, Business Development at EmendoBio | Developing Cutting Edge Gene Editing Technologies for Rare Diseases
- Role
- Vice President of Business Development Cutting Edge Novel Nuclease Gene Editing Platform at Emendobio
- Location
- Cambridge, MA, US
- LinkedIn followers
- 500 followers
About Prashant Kudva
Experienced business development professional focused on sourcing, evaluating…
Experience
Vice President of Business Development Cutting Edge Novel Nuclease Gene Editing Platform
Mar 2023 — Present · Cambridge, MA, US
EmendoBio is a biotechnology company with a cutting-edge next generation gene editing company that has a discovery platform that utilizes AI/ML to create an unprecedented library of nucleases that can target 80+% of the human genome. Internal programs are in rare disease, hematology and cardiometabolic disease. Lead partnerships, collaborations, licensing, M&A and other strategic transactions. Focused on creating improved therapies by outlicensing nucleases to cell therapy companies. Other projects include acquiring potential enabling technologies and strategically crafting business development plans. Most initiatives were cross-border or global.
Education
The London School of Economics and Political Science (LSE)
Non-Degree Course
Harvard University
Masters Level Courses
HMX – Harvard Medical School
Certificate
University of Pennsylvania
Certificate
University of Chicago
Bachelor's degree
The Johns Hopkins University
Master's degree
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.